Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by R.K. Singh
Total Records ( 2 ) for R.K. Singh
  V. Bhanuprakash , M. Hosamani , V. Balamurugan , R.K. Singh and D. Swarup
  Buffalopox is one of the zoonotic infections having a significant public health impact. The virus is closely related to Vaccinia virus. There is no prophylactic available to combat the buffalopox infection. Ample number of reports is available indicating the use of herbal preparations for veterinary use in India. In this resesrch, four plants having known medicinal importance were screened for buffalopox virus inhibition in vitro. Of the four plant tested, extract from Eugenia jambolana leaves had an inhibition of 98.52% at its maximum non toxic concentration (1999.730.50 g mL 1) in all cytopathic effect inhibition assays. The inhibition of buffalopox virus replication was further confirmed using PCR (ATI and C18Lgenes) and Real Time-PCR (C18L gene) assays specific for buffalopox virus. Our results indicate that the extract from Eugenia jambolana leaves inhibit the buffalopox virus in vitro.
  Balamurugan, V. , A. Sen , P. Saravanan and R.K. Singh
  Recombinant DNA (rDNA) technology has indeed made tremendous breakthrough in the discovery of various vaccines or diagnostic antigens. The advent of rDNA technology and its application in the industry has brought about a rapid growth of biotechnology companies for the production of the rDNA products in human and animal healthcare. The new generation vaccines prepared from the viral/microbial proteins; their fragments or the nucleic acid sequences have been attractive because of their stability, non-infectious nature, homogeneity as well as their cost-effectiveness. Several products are undergoing clinical trials and finally products approval by FDA/FAO/OIE is required before its use in human/animals. Products developed in the field of veterinary prophylactics and diagnostics will be most valuable for further development of rDNA products in the coming decades and advances in biotechnology have also created many legal issues particularly patent. The Biotech industry Guide would be useful for industrial approval, regulatory clearance to rDNA product and biosafety aspects. In view of high market potential for recombinant therapeutics as the case with human therapeutics, indigenous technology should also be developed for the veterinary field to develop a prophylactics and diagnostics. This general article provides collected information regarding production of recombinant proteins and their use in Veterinary science along with brief description of various heterologous expressed systems and their potential applications for the production of recombinant products.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility